|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | shRNA targeting HDGF suppressed cell growth and invasion of squamous cell lung cancer显示文摘导出 Hepatoma 的生长因素(HDGF ) ,有 mitogenic 的原子蛋白质和 angiogenic 活动,被报导了主要涉及 tumorigenesis 和非小的房间肺癌症的前进。在这研究, HDGF 表示被 specific-shRNA 与在肺指向 HDGF 的 lentivirus 表示向量击倒有鳞的房间癌 520 房间。shRNA 击倒的 HDGF 在 vitro 并且在由 MTT,板克隆和移植肿瘤模型试金显示了的 vivo 显著地压制了房间增长。另外, HDGF 的组合式的表达式也禁止了出现在 transwell 和 Boyden 实验的房间移植和侵略。因为参予有鳞的房间肺癌症的致病的 oncogene,和 HDGF 可以是为非小的房间肺癌症的一个关键治疗学的目标,我们断定 HDGF 行动。 | Jie Meng Wei Xie Liming Cao Chengping Hu Zhiyuan Zhen | 2010 | Acta Biochimica et Biophysica Sinica2010，42，1： | 19 |
| 2 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 7 |
| 3 | Low-intensity aerobic exercise training attenuates airway inflammation and remodeling in a rat model of steroid-resistant asthma显示文摘 | Qin Qingwu Chen Xi Feng Juntao Qin Ling Hu Chengping | 2014 | Chinese Medical Journal2014，，17： | 4 |
| 4 | Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients显示文摘Objective: Germline alterations in the breast cancer susceptibility genes type 1 and 2, BRCA1 and BRCA2, predispose individuals to hereditary cancers, including breast, ovarian, prostate, pancreatic, and stomach cancers.Accumulating evidence suggests inherited genetic susceptibility to lung cancer.The present study aimed to survey the prevalence of pathogenic germline BRCA mutations(gBRCAm) and explore the potential association between gBRCAm and disease onset in Chinese advanced non-small cell lung cancer(NSCLC) patients.Methods: A total of 6,220 NSCLC patients were screened using capture-based ultra-deep targeted sequencing to identify patients harboring germline BRCA1/2 mutations.Results: Out of the 6,220 patients screened, 1.03%(64/6,220) of the patients harbored the pathogenic gB RCAm, with BRCA2 mutations being the most predominant mutations(49/64, 76.5%).Patients who developed NSCLC before 50 years of age were more likely to carry gBRCAm(P = 0.036).Among the patients harboring classic lung cancer driver mutations, those with concurrent gBRCAm were significantly younger than those harboring the wild-type gBRCA(P = 0.029).By contrast, the age of patients with or without concurrent gBRCAm was comparable to those of patients without the driver mutations(P = 0.972).In addition, we identified EGFR-mutant patients with concurrent gBRCAm who showed comparable progression-free survival but significantly longer overall survival(P = 0.002) compared to EGFR-mutant patients with wild-type germline BRCA.Conclusions: Overall, our study is the largest survey of the prevalence of pathogenic gBRCAm in advanced Chinese NSCLC patients.Results suggested a lack of association between germline BRCA status and treatment outcome of EGFR-TKI.In addition,results showed a positive correlation between pathogenic gB RCAm and an early onset of NSCLC. | Xingsheng Hu Dongyong Yang Yalun Li Li Li Yan Wang Peng Chen Song Xu Xingxiang Pu Wei Zhu Pengbo Deng Junyi Ye Hanhan Zhang Analyn Lizaso Hao Liu Xinru Mao Hai Huang Qian Chu Chengping Hu | 2019 | Cancer Biology & Medicine2019，16，3： | 4 |
| 5 | Nerve growth factor and nerve growth factor receptors in respiratory syncytial virus -infected lungs 显示文摘 | Chengping Hu Katrin Wedde - Beer Alexander Auais | 2002 | Am J Physiol Lung Cell Mol Physiol2002，283，2： | 1 |
| 6 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 1 |
| 7 | Clinical characteristics and prognostic significance of 92 cases ofpatients with primary mixed?histology lung cancer显示文摘 | Pengbo Deng Chengping Hu Lihua Zhou Yuanyuan Li Li Huang | 2013 | Molecular and Clinical Oncology2013，，5： | 1 |
| 8 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 1 |
| 9 | Erratum to Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients显示文摘In the published article1,the affiliation for the first author,Xingshcng Hu,is'Department of Medical Oncology,Cancer Hospital,Chinese Academy of Medical Sciences',we would like to update it to'Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,100021,China'.We apologize for the errors and for any confusion it may have caused. | Xingsheng Hu Dongyong Yang Yalun Li Li Li Yan Wang Peng Chen Song Xu Xingxiang Pu Wei Zhu Pengbo Deng Junyi Ye Hanhan Zhang Analyn Lizaso Hao Liu Xinru Mao Hai Huang Qian Chu Chengping Hu | 2020 | Cancer Biology & Medicine2020，17，2： | 1 |
| 10 | Good response of malignant pleural effusion from carcinoma of unknown primary site to the anti-tuberculosis therapy: A case re- port显示文摘 | Qihua Gu Chengping Hu Jingjing Qu | 2013 | International Journal of Clinical and Experimen- tal Pathology2013，6，5： | 1 |
| 11 | Nerve growth factor and nerve growth factor receptors in respiratory syncytial virus-infected lungs 显示文摘 | Hu Chengping Katrin Wedde-beer Alexander Auals | 2002 | Am J Physiol Lung Cell Mol Physiol2002，283，2： | 1 |
| 12 | Development of a rat model by 3, 4-benzopyrene intra- pulmonary injection and evaluation of the effect of green tea drinking on p53 and bcl-2 expression in lung carcinoma显示文摘 | GU QIHUA CHENGPING HU QIONG CHEN | 2009 | Cancer Detection and Prevention2009，32，5： | 1 |
| 13 | Bronchial Fistula: Rare Complication of Treatment with Anlotinib显示文摘Background and objective Anlotinib is a newly developed small molecule multiple receptor tyrosine kinase(RTK) inhibitor that was approved for the treatment of patients with lung cancer in China. We aim to report 3 cases of rare complication of anlotinib-bronchial fistula(BF) during the treatment of lung cancer patients and summarize the possible causes.Methods We collected three patients who developed BF due to anlotinib treatment, and conducted a search of Medline and Pub Med for medical literature published between 2018 and 2020 using the following search terms: 'anlotinib,' 'lung cancer,' and 'fistula.'Results Our literature search produced two case reports(three patients) which, in addition to our three patients. We collated the patients’ clinical characteristics including demographic information, cancer type, imaging features, treatment received, risk factors for anlotinib related BF, and treatment-related outcomes. The six patients shared some common characteristics: advanced age, male, concurrent infection symptoms, diabetes mellitus(DM), advanced squamous cell and small cell lung cancers, centrally located tumors, tumor measuring ≥5 cm in longest diameter, and newly formed tumor cavitation after multi-line treatment especially after receiving radiotherapy. Fistula types included broncho-pericardial fistula, broncho-pleural fistula, and esophagotracheobronchial fistula. Six patients all died within 6 months.Conclusion Although anlotinib is relatively safe, it is still necessary to pay attention to the occurrence of BF, a rare treatment side effect that threatens the quality of life and overall survival of patients. Anlotinib, therefore, requires selective use and close observation of high-risk patients. | Pengbo DENG Chengping HU Yuanyuan LI Liming CAO Huaping YANG Min LI Jian AN Juan JIANG Qihua GU | 2020 | 中国肺癌杂志2020，23，10： | 1 |
| 14 | Development of a rat model by 3,4-benzopyrene intra-pulmonary injection and evaluation of the effect of green tea drinking on p53 and bcl-2 expression in lung carcinoma显示文摘 | Qihua Gu Chengping Hu Qiong Chen Ying Xia Juntao Feng Hongzhong Yang | | Cancer Epidemiology0，，： | 1 |
| 15 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study显示文摘 | Caicun Zhou Yi-Long Wu Gongyan Chen Jifeng Feng Xiao-Qing Liu Changli Wang Shucai Zhang Jie Wang Songwen Zhou Shengxiang Ren Shun Lu Li Zhang Chengping Hu Chunhong Hu Yi Luo Lei Chen Ming Ye Jianan Huang Xiuyi Zhi Yiping Zhang Qingyu Xiu Jun Ma Li Zhang C | 2011 | Lancet Oncology2011，，8： | 1 |
| 16 | Theanine improves the function of dendritic cells via the downregulation of cyclooxygenase-2 expression显示文摘 | Lei Mingsheng Zuo Jianhong Li Min Gu Qihua Hu Chengping | 2014 | Chinese Medical Journal2014，，8： | 0 |
| 17 | An Environmentally Benign Catalytic Method for Versatile Synthesis of 1,4-Dihydropyridines via Multicomponent Reactions显示文摘The synthesis of diverse 1,4-dihydropyridines have been achieved via the multicomponent reactions of aldehydes,enaminones and amines.The reactions have been smoothly performed in water to provide all products with moderate to excellent yields by using lactic acid as a green catalyst. | Shuo Cao Shanshan Zhong Changfeng Hu Jie-Ping Wan Chengping Wen | 2015 | Chinese Journal of Chemistry2015，33，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员